Kidney Failure, Acute Clinical Trial
Official title:
Study of the Quantitative Evolution of Circulating Cell-free DNA of Renal Origin in Patients With Acute Renal Failure
The amount of total circulating DNA has been shown to increase in patients with acute renal failure. Nevertheless, it is currently not currently possible to prove the renal origin of this circulating DNA. Recently, in healthy subjects, teams have shown that it is possible to identify its tissue origin of circulating DNA. CGenetix is a MedTech company which develops on an identical principle an in vitro diagnostic test capable of identifying and quantifying renal degradation during an acute trauma. The objective of this study is to evaluate the sensitivity of the proposed technology to detect circulating DNA of renal origin released into the general circulation in patients with acute organic and functional renal failure. Patients with functional or organic kidney deficiency will be included and the kidney biomarkers develop by CGenetix will be compared between these 2 groups of patients.
When the patient arrives, a first stage of checking the inclusion/non-inclusion criteria will be respected. Patients who do not meet the eligibility criteria will not be sampled (pre-screening stage). Patients meeting the eligibility criteria will be informed of the study by the investigator and a written information note will be given to them. If they do not object to their participation, an additional tube of blood for research purposes will be taken during a blood sample taken as soon as they are admitted as part of their usual treatment. They will also follow the standard care protocol according to the clinical recommendations of their attending physician. The objective of early sampling is to sensitize the test by assaying the marker as soon as possible after renal injury. In the event of a posteriori differential diagnosis (obstructive ARF or IRC), the patient will be excluded from the final analysis. Patients passing the pre-screening and screening stages positively will be included in the final analysis. 90 patients should be included and divided into 2 groups: - 65 patients with non-biopsied organic acute kidney injury of which 20 patients with biopsied organic acute kidney injury (test group) - 25 patients with functional acute kidney failure (control group). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00982527 -
Fenoldopam in Pediatric Cardiac Surgery
|
Phase 3 | |
| Completed |
NCT00908843 -
Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration
|
N/A | |
| Completed |
NCT00654992 -
Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery
|
Phase 2/Phase 3 | |
| Completed |
NCT05407272 -
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
|
N/A | |
| Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
| Completed |
NCT04072432 -
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3-4 Chronic Kidney Disease
|
Phase 1 | |
| Recruiting |
NCT00230412 -
Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)
|
N/A | |
| Completed |
NCT00148044 -
Uremic Toxins of Patients With Acute Kidney Failure
|
N/A | |
| Active, not recruiting |
NCT04450095 -
Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery
|
Phase 2 | |
| Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
| Completed |
NCT03353389 -
Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang
|
||
| Completed |
NCT03727581 -
Ultrasound for Guidewire Detection
|
||
| Completed |
NCT00912184 -
Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00522756 -
Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy
|
Phase 3 | |
| Terminated |
NCT00316576 -
Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)
|
N/A | |
| Completed |
NCT00484354 -
Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery
|
Phase 2 | |
| Completed |
NCT00122018 -
An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
|
Phase 2 | |
| Unknown status |
NCT01359722 -
N-acetylcysteine to Prevent Renal Failure
|
N/A | |
| Completed |
NCT00286273 -
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
|
Phase 4 | |
| Completed |
NCT03476460 -
Sodium Chloride and Contrast Nephropathy
|
Phase 2 |